CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

• Data confirm CV8102’s safety and ability to strongly mobilize the immune system against tumors
• Final data of complete Phase 1 dose-escalation and expansion study expected in H1 2023

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced data from the Phase 1 expansion study of CV8102, the company’s non-coding RNA candidate in oncology. Preliminary results from the completed Phase 1 expansion study in patients with PD-1 refractory melanoma confirm a robust safety profile of CV8102 as a single agent and in combination with anti-PD-1 antibodies. Preliminary efficacy was observed in a cohort of 30 patients treated in combination with anti-PD-1 antibodies, 40% of whom were pretreated with anti-CTLA-4 antibodies. As of June 15, 2022, in the anti-PD-1 combination cohort, five out of 30 patients (17%) experienced a partial response according to RECIST 1.1. Responses appeared durable for up to one year from the start of treatment. No objective responses were observed in the 10 patients of the single-agent cohort, 50% of whom were pretreated with anti-CTLA-4 antibodies. The data will be presented today at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held in Boston, Massachusetts.

CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

• Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studies
  • Phase 1 initiated for modified COVID-19 vaccine candidate CV0501, targeting Omicron variant
  • Phase 1 initiated for modified influenza vaccine candidate FLU SV mRNA
• Accelerating oncology strategy with complementary technology platforms and strong leadership support
  • Acquisition of Frame Cancer Therapeutics adds advanced genomics and bioinformatics capabilities to feed pipeline of cancer vaccine candidates
  • Appointment of Dr. Myriam Mendila, M.D., as Chief Development Officer adds international experience and expertise in building a broad oncology product portfolio
• Cash position of €573.6 million as of June 30, 2022; decreasing headwind of wind-down costs for first-generation COVID-19 vaccine program

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the second quarter and first half of 2022 and provided a business update.

CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”) today announced that it has moved to assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development. CureVac has filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech SE and two of its subsidiaries, seeking fair compensation for infringement of a portfolio of CureVac’s intellectual property rights, EP 1 857 122 B1, DE 20 2015 009 961 U1, DE 20 2021 003 575 U1 and DE 20 2015 009 974 U1, utilized in the manufacture and sale of Comirnaty®, BioNTech and Pfizer’s mRNA COVID-19 vaccine. CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale or distribution of Comirnaty® by BioNTech and its partner Pfizer.

CureVac Announces Changes of CDO – Myriam Mendila to succeed Klaus Edvardsen

• Myriam Mendila appointed as Chief Development Officer starting from February 1, 2023
• Klaus Edvardsen returning to Denmark after holding numerous leadership positions in the U.S. and Europe
• Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”) today announced that Chief Development Officer Klaus Edvardsen will leave the company on June 30, 2022. He plans to return home to Denmark for a new professional opportunity. CureVac is pleased to welcome Myriam Mendila to this key role. Myriam’s appointment will take effect on February 1, 2023. Until then, Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer.

CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

• CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone
• The partnership combines CureVac’s mRNA technology with myNEO’s platform for the discovery and selection of tumor antigens predicted to elicit strong immune responses
• Together with myNEO, CureVac aims to identify specific antigens for the development of novel mRNA cancer vaccines

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and myNEO N.V., a Belgium-based immunotherapy company, today announced that they have entered into a research and option agreement. Under the agreement, both companies aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. To achieve this goal, myNEO will leverage its biological datasets and its integrated machine learning and bioinformatics platform to identify and validate specific antigen targets predicted to elicit a strong immune response.